Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

Teva Pharmaceutical Industries Ltd.'s bid to dismiss antitrust claims should be denied in a case where Mylan Pharmaceuticals Inc. alleges the company unlawfully delayed a generic version of a multiple ...

NEW YORK CITY, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income ...

As an enterprise engaged in the development, manufacturing and commercialization of specialty plasma-derived therapeutics, ...

In particular, the third quarter of the fiscal year also saw record revenue and margins, with the gross margin improving by 1.6 percentage points from 58.7% to 60.3%. The company's UGG and Hoka brands ...

Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) reported fourth-quarter adjusted EPS of 92 cents, up from 88 cents a year ago, ...

The Board of Health voted this week to recommend these $10,000 simulated high school parties featuring student actors, using a settlement from a state lawsuit against Teva Pharmaceuticals.

The S&P 500 (SP500) hit new highs during February trade, but that wasn’t enough to stave off a monthly loss. The benchmark ...

Stanley Druckenmiller is a retired hedge fund manager of Duquesne Capital, which focuses on macro investment strategy. His fund constantly delivered high returns, and in 2010, when the fund failed to ...

Corneal Ulcer Treatment MarketThe global corneal ulcer treatment market is projected to grow at a CAGR of 5.2% from 2024 to 2034, reaching a market value of USD 1,601.1 million by 2034. In 2024, the ...